Sildenafil for pulmonary hypertension in neonates

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 8, 2017, Pages

  Kelly, Lauren E ^a   Ohlsson, Arne ^b   Shah, Prakeshkumar S ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MAGNESIUM SULFATE; NITRIC OXIDE; PLACEBO; SILDENAFIL; VASODILATOR AGENT; BRONCHODILATING AGENT;

ADJUVANT THERAPY; ARTERIAL OXYGEN TENSION; ARTIFICIAL VENTILATION; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOLLOW UP; GESTATIONAL AGE; HEMODYNAMIC PARAMETERS; HUMAN; LENGTH OF STAY; LUNG VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; MORTALITY; NEWBORN; NEWBORN CARE; OUTCOME ASSESSMENT; OXYGENATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTEMIC VASCULAR RESISTANCE; TREATMENT DURATION; TREATMENT RESPONSE; CAUSE OF DEATH; HYPERTENSION, PULMONARY; META ANALYSIS;

BRONCHODILATOR AGENTS; CAUSE OF DEATH; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; NITRIC OXIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SILDENAFIL CITRATE; VASODILATOR AGENTS;

EID: 85026816609     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005494.pub4     Document Type: Review

References (63)

1. Al Omar S, Salama H, Al Hail M, Al Rifai H, Bunahia M, El Kasem W, et al. Effect of early adjunctive use of oral sildenafil and inhaled nitric oxide on the outcome of pulmonary hypertension in newborn infants. A feasibility study. Journal of Neonatal-Perinatal Medicine 2016;9(3):251-9. [DOI: 10.3233/NPM-16161; PUBMED: 27589542]6474786
2. Baquero H, Neira F, Venegas ME, Sola A, Soliz A. Outcome at 18 months of age after sildenafil therapy for refractory neonatal hypoxemia. Pediatric Academic Societies' Annual Meeting; 2005 May 14-17; Washington DC, United States 2005;57:2119. [PAS 2005: 57: 2119]2757136
3. Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 2006;117(4):1077-83. [DOI: 10.1542/peds.2005-0523; PUBMED: 16585301]2757137
4. Herrea TR, Concha GP, Holberto CJ, Loera GRG, Rodríguez BI. Oral sildenafil as an alternative treatment in the persistent pulmonary hypertension in newborns [Sildenafil oral como alternativa en el tratamiento de recien nacidos con hipertension pulmonar persistente]. Revista Mexicana de Pediatria 2006;73(4):159-63. 2757139
5. Uslu S, Kumtepe S, Bulbul A, Comert S, Bolat F, Muhoglu A. A comparison of magnesium sulphate and sildenafil in the treatment of the newborns with persistent pulmonary hypertension; a randomized controlled trial. Journal of Tropical Pediatrics 2011;57(4):245-50. [DOI: 10.1093/tropej/fmq091; PUBMED: 20923790]6474788
6. Vargas-Origel A, Gomez-Rodriguez G, Aldana-Valenzuela C, Vela-Huerta MM, Alarcon-Santos SB, Amador-Licona N. The use of sildenafil in persistent pulmonary hypertension of the newborn. American Journal of Perinatology 2010;27(3):225-30. [DOI: 10.1055/s-0029-1239496; PUBMED: 19866403]2757141
7. Khaveci H, Yilmaz O, Avsar UZ, Ciftel M, Kilic M, Laloglu F, et al. Oral sildenafil and inhaled iloprost in the treatment of pulmonary hypertension of the newborn. Pediatric Pulmonology 2014;49(12):1205-13. [DOI: 10.1002/ppul.22985; PUBMED: 24420987]6474790
8. König K, Barfield CP, Guy KJ, Drew SM, Anderson CC. The effect of sildenafil on evolving bronchopulmonary dysplasia in extremely preterm infants: a randomised controlled pilot study. Journal of Maternal-Fetal & Neonatal Medicine 2014;27(5):439-44. [DOI: 10.3109/14767058.2013.818650; PUBMED: 23796045]6474792
9. Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ, Shekerdemian LS. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. American Journal of Respiratory and Critical Care Medicine 2006;174(9):1042-7. [DOI: 10.1164/rccm.200605-694OC; PUBMED: 16917115]2757143
10. Sayed A, Bisheer N. Outcome of oral sildenafil in neonatal persistent pulmonary hypertension of non-cardiac causes. Journal of Neonatal-Perinatal Medicine 2015;8(3):215-20. [DOI: 10.3233/NPM-15814137; PUBMED: 26485555]6474794
11. Steinhorn RH, Kinsella JP, Pierce C, Butrous G, Dilleen M, Oakes M, et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. Journal of Pediatrics 2009;155(6):841-7. [DOI: 10.1016/j.jpeds.2009.06.012; PUBMED: 19836028]2757145
12. Stocker C, Penny DJ, Brizard CP, Cochrane AD, Soto R, Shekerdemian LS. Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Medicine 2003;29(11):1996-2003. [DOI: 10.1007/s00134-003-2016-4; PUBMED: 14530859]2757147
13. Alipour MR, Lookzadeh MH, Namayandeh SM, Pezeshkpour Z, Sarebanhassanabadi M. Comparison of tadalfil and sildenafil in controlling neonatal persistent pulmonary hypertension. Iran Journal of Pediatrics 2017;27(1):6385-9. [DOI: 10.5812/ijp.6385]6474796
14. NCT01373749. Nitro oxide inhalation continued with sildenafil on neonatal persistent pulmonary hypertension [Compare of continued nitro oxide inhalation and nitro oxide inhalation continued with oral sildenafil on treatment of neonatal persistent pulmonary hypertension]. clinicaltrials.gov/show/NCT01373749 (first received 31 May 2011). 6474798
15. NCT01757782. Oral sildenafil in persistent pulmonary hypertension secondary to meconium aspiration syndrome in newborns [Oral sildenafil in persistent pulmonary hypertension secondary to meconium aspiration syndrome in newborns: a randomized placebo controlled trial]. clinicaltrials.gov/show/NCT01757782 (first received 18 December 2012). [ClinicalTrials.gov: NCT01757782]6474800
16. Soliz A, Concha E, Romero F. Oral sildenafil treatment as therapy for persistent pulmonary hypertension of the newborn: a multicenter randomized trial. Pediatric Academic Societies' Annual Meeting; 2009 May 2-5; Baltimore MD, United States. 2009. [E-PAS2009:5420.12]2757151
17. NCT01720524. A study to evaluate safety and efficacy of IV sildenafil in the treatment of neonates with persistent pulmonary hypertension of the newborn. clinicaltrials.gov/show/NCT01720524 (first received 17 September 2012). 6474802
18. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000;84(2):E4. [PUBMED: 10908271]
19. Adatia I. Recent advances in pulmonary vascular disease. Current Opinion in Pediatrics 2002;14(3):292-7. [PUBMED: 12011667]
20. Barrington KJ, Finer NN. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD000509.pub4]
21. Behn D, Potter MJ. Sildenafil-mediated reduction in retinal function in heterozygous mice lacking the gamma-subunit of phosphodiesterase. Investigative Ophthalmology and Visual Science 2001;42(2):523-7. [PUBMED: 11157892]
22. Burton AJ, Reynolds A, O'Neill D. Sildenafil (Viagra) a cause of proliferative diabetic retinopathy?. Eye 2000;14(Pt 5):785-6. [DOI: 10.1038/eye.2000.205; PUBMED: 11116706]
23. Carroll WD, Dhillon R. Sildenafil as a treatment for pulmonary hypertension. Archives of Disease in Childhood 2003;88(9):827-8. [PUBMED: 12937112]
24. Dukarm RC, Morin FC, Russell JA, Steinhorn RH. Pulmonary and systemic effects of the phosphodiesterase inhibitor dipyridamole in newborn lambs with persistent pulmonary hypertension. Pediatric Research 1998;44(6):831-7. [DOI: 10.1203/00006450-199812000-00002; PUBMED: 9853914]
25. Erickson S, Reyes J, Bohn D, Adatia I. Sildenafil (Viagra) in childhood and neonatal pulmonary hypertension. Journal of the American College of Cardiology 2002;39:402.
26. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database of Systematic Reviews 2017, Issue 1. [DOI: 10.1002/14651858.CD000399.pub3]
27. Gersony WM. Neonatal pulmonary hypertension: pathophysiology, classification, and etiology. Clinics in Perinatology 1984;11(3):517-24. [PUBMED: 6488670]
28. Goldman AP, Tasker RC, Haworth SG, Sigston PE, Macrae DJ. Four patterns of response to inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics 1996;98(4 Pt 1):706-13. [PUBMED: 8885950]
29. GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 19 April 2017. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
30. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. handbook.cochrane.org.
31. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. New England Journal of Medicine 2004;351(14):1425-36. [DOI: 10.1056/NEJMra040291; PUBMED: 15459304]
32. Iacovidou N, Syggelou A, Fanos V, Xanthos T. The use of sildenafil in the treatment of persistent pulmonary hypertension of the newborn: a review of the literature. Current Pharmaceutical Design 2012;12(21):3034-45. [PUBMED: 22564297]
33. Ichinose F, Erana-Garcia J, Hromi J, Raveh Y, Jones R, Krim L, et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Critical Care Medicine 2001;29(5):1000-5. [PUBMED: 11378612]
34. Ikeda D, Tsujino I, Ohira H, Itoh N, Kamigaki M, Ishimaru S, et al. Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension. Journal of Cardiovascular Pharmacology 2005;45(4):286-9. [PUBMED: 15772514]
35. Juliana AE, Abbad FC. Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil. European Journal of Pediatrics 2005;164(10):626-9. [DOI: 10.1007/s00431-005-1724-x; PUBMED: 16012855]
36. Kanthapillai P, Lasserson T, Walters E. Sildenafil for pulmonary hypertension. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD003562.pub2]
37. Kehat R, Bonsall DJ, North R, Connors B. Ocular findings of oral sildenafil use in term and near-term neonates. Journal of AAPOS 2010;14(2):159-62. [DOI: 10.1016/j.jaapos.2009.12.161; PUBMED: 20199882]
38. Kinsella JP, Abman SH. Inhaled nitric oxide: current and future uses in neonates. Seminars in Perinatology 2000;24(6):387-95. [PUBMED: 11153900]
39. Kumar S. Indian doctor in protest after using Viagra to save "blue babies". British Medical Journal 2002;325(7357):181. [PUBMED: 12142299 ]
40. Lewin S. Viagra neonatal experimentation - the Pandora's box!. Indian Pediatrics 2002;39(9):894-5. [PUBMED: 12368555]
41. Marsh CS, Marden B, Newsom R. Severe retinopathy of prematurity (ROP) in a premature baby treated with sildenafil acetate (Viagra) for pulmonary hypertension. British Journal of Ophthalmology 2004;88(2):306-7. [PUBMED: 14736800]
42. Mesubi OO, Ashwath R, Mhanna MJ. Oral sildenafil in premature infants with pulmonary arterial hypertension secondary to bronchopulmonary dysplasia. Pediatric Academic Societies Annual meeting; 2009 May 2-5; Baltimore MD, United States. 2009. [E-PAS2009:615]
43. Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. Journal of Pediatrics 2009;154(3):379-84. [DOI: 10.1016/j.jpeds.2008.09.021; PUBMED: 18950791]
44. Oliver J, Webb DJ. Sildenafil for "blue babies". Such unlicensed drug use might be justified as last resort. British Medical Journal 2002;325(373):1174. [PUBMED: 12433774]
45. Patole S, Travadi J. Sildenafil for "blue babies". Ethics, conscience, and science have to be balanced against limited resources. British Medical Journal 2002;325(7373):1174. [PUBMED: 12434819]
46. Pierce CM, Petros AJ, Fielder AR. No evidence for severe retinopathy of prematurity following sildenafil. British Journal of Ophthalmology 2005;89(2):250. [PUBMED: 15665374]
47. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. American Journal of Physiology 1994;266(5 Pt 1):L536-43. [PUBMED: 7515580]
48. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
49. Roberts JD Jr, Fineman JR, Morin FC 3rd, Shaul PW, Rimar S, Schreiber MD, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. New England Journal of Medicine 1997;336(9):605-10. [DOI: 10.1056/NEJM199702273360902; PUBMED: 9032045]
50. Sastry BKS, Narasimhan C, Reddy K, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension. Journal of the American College of Cardiology 2004;43(7):1149-53. [DOI: 10.1016/j.jacc.2003.10.056; PUBMED: 15063421]
51. Schünemann H, Brozek J, Guyatt G, Oxman A, editors. GRADE Working Group. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. https://gdt.gradepro.org/app/handbook/handbook.html Updated October 2013.
52. Shah PS, Hellmann J, Adatia I. Clinical characteristics and follow up of Down syndrome infants without congenital heart disease who presented with persistent pulmonary hypertension of newborn. Journal of Perinatal Medicine 2004;32(2):168-70. [DOI: 10.1515/JPM.2004.030; PUBMED: 15085894]
53. Shekerdemian LS, Ravn HB, Penny DJ. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 2002;165(8):1098-102. [DOI: 10.1164/ajrccm.165.8.2107097; PUBMED: 11956051]
54. Shekerdemian LS, Ravn HB, Penny DJ. Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. Pediatric Research 2004;55(3):413-8. [DOI: 10.1203/01.PDR.0000112033.81970.C2; PUBMED: 14711900]
55. Shivanna B, Eichenwald EC, Stark AR. Sildenafil use in the newborn intensive care units is associated with improvement in pulmonary hypertension. Pediatric Academic Societies' Annual Meeting; 2009 May 2-5; Baltimore MD, United States 2009. [E-PAS2009:621]
56. Simiyu DE, Okello C, Nyakundi EG, Tawakal AH. Sildenafil in management of persistent pulmonary hypertension of the newborn: report of two cases. East African Medical Journal 2006;83(6):337-40. [PUBMED: 16989380]
57. Spillers J. PPHN: is sildenafil the new nitric? A review of the literature. Advances in Neonatal Care 2010;10(2):69-74. [DOI: 10.1097/ANC.0b013e3181d5c501; PUBMED: 20386371]
58. Subhedar NV, Jauhari P, Natarajan R. Cost of inhaled nitric oxide therapy in neonates. Lancet 2002;359(9319):1781-2. [DOI: 10.1016/S0140-6736(02)08632-4; PUBMED: 12049900]
59. Travadi JN, Patole SK. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. Pediatric Pulmonology 2003;36(6):529-35. [DOI: 10.1002/ppul.10389; PUBMED: 14618646]
60. Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000;105:14-20.
61. Wessel DL, Adatia I, Van Marter LJ, Thompson JE, Kane JW, Stark AR, et al. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics 1997;100:e7.
62. Shah PS, Ohlsson A. Sildenafil for pulmonary hypertension in neonates. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD005494.pub2; PUBMED: PMID: 17636802]
63. Shah PS, Ohlsson A. Sildenafil for pulmonary hypertension in neonates. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD005494.pub3; PUBMED: PMID 21833954 ]